
|Articles|October 5, 2010
Look for upcoming Practice & Policy in November edition of ONCOLOGY
Author(s)Michael Mccaughan
Second-Guessing FDA: CMS’ Expanding Regulatory Role
Advertisement
Nothing gets biopharma policy watchers more worked up than the potential that the Centers for Medicare & Medicaid Services will second-guess FDA approval decisions. In reality, though, CMS often has no choice but to apply its own interpretation to issues that also fall under FDA’s jurisdiction-and the health care reform implementation is bringing more of those cases to the fore...
Check out the complete article by an award-winning journalist in the upcoming edition of ONCOLOGY...
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Accepts NDA for Zanzalintinib/Atezolizumab in Pretreated Metastatic CRC
2
How Would the Teclistamab Combo Approval Transform Multiple Myeloma?
3
Early Time-of-Day Chemoimmunotherapy Boosts Survival in NSCLC
4
Dato-DXd Receives Priority Review in Unresectable/Metastatic TNBC
5



































